On Thursday, Shares of Baxter International Inc. (NYSE:BAX), lost -1.44% to $38.30.
Baxter International Inc., declared the preliminary results, as of 5:00 p.m. New York City time on July 1, 2015, of its formerly declared cash tender offers for specified series of its outstanding debt. As of the Early Tender Time, the aggregate principal amount of notes listed in the table below validly tendered and not validly withdrawn following the Any and All Tender Offer (as defined in Baxter’s Offer to Purchase dated June 18, 2015, the ”Offer to Purchase”) was about $1.1 billion and the aggregate principal amount of notes validly tendered and not validly withdrawn following the Maximum Tender Offer (as defined in the Offer to Purchase) was about $1.6 billion.
The terms and conditions of the Tender Offers are described in the Offer to Purchase and the related Letter of Transmittal. The Tender Offers are presently planned to expire at 11:59 p.m. NYC time on July 16, 2015 (the ”Expiration Time”).
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products.
Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), declined -0.62% to $3.23, during its last trading session.
Sunesis Pharmaceuticals, declared that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the Cantor Fitzgerald Inaugural Healthcare Conference on Wednesday, July 8th at 9:00 AM Eastern Time at Le Parker Meridien Hotel in New York City.
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Finally, HollyFrontier Corporation (NYSE:HFC), ended its last trade with 1.93% gain, and closed at $44.82.
HollyFrontier Corporation, plans to declare results for its quarter ended June 30, 2015 on August 5, 2015, before the opening of trading on the NYSE. The Company has planned a webcast conference on August 5, 2015 at 8:30 a.m. Eastern time to talk about financial results.
HollyFrontier Corporation operates as an independent petroleum refiner in the United States. The company operates in two segments, Refining and HEP. It produces high-value refined products, such as gasoline, diesel fuel, jet fuel, specialty lubricant products, liquid petroleum gas, fuel oil, and specialty and modified asphalt.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
